NDATOPICALCREAM
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VANIQA (eflornithine hydrochloride) by AbbVie is clinical pharmacology. Approved for hirsutism. First approved in 2000.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANIQA (eflornithine HCl) is a topical cream approved in 2000 for the treatment of facial hirsutism in women. It works by inhibiting ornithine decarboxylase (ODC), an enzyme critical to polyamine synthesis, thereby slowing hair growth. The mechanism reduces the proliferation and differentiation of hair follicle cells.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams are likely consolidating and shifting focus to retention and managed care strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY
Indications (1)
Career Relevance
Working on VANIQA offers limited career growth given the LOE-approaching lifecycle stage and niche indication (hirsutism). This product is best suited for professionals seeking stability in a mature brand rather than high-visibility launch or expansion opportunities.
Brand Manager
Worked on VANIQA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.